Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 8, Issue 6 (2019)

GLP-1 agonists for the treatment of type 2 diabetes: Hype or hope?

Author(s):
Dr. Vipul Gupta and Dr. Girish Khurana
Abstract:
The incretin system has become an crucial target in the treatment of type 2 diabetes in modern years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects. Glucagon-like peptide-1 (GLP-1)–based therapy betters glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pancreas, tremendous progress has been made in the area of incretins. Proper patient selection and education can assist in achieving positive treatment outcomes.
Pages: 1117-1120  |  432 Views  45 Downloads


The Pharma Innovation Journal
How to cite this article:
Dr. Vipul Gupta, Dr. Girish Khurana. GLP-1 agonists for the treatment of type 2 diabetes: Hype or hope?. Pharma Innovation 2019;8(6):1117-1120.

Call for book chapter